A bone marrow biopsy report is not a single document you read top to bottom like a letter from your doctor. It arrives in layers, sometimes over days or even weeks, as different laboratory tests finish at different speeds. The core of the report describes what the pathologist saw under the microscope, but it also folds in results from flow cytometry, genetic testing, and molecular sequencing. Understanding the report means knowing what each section is telling you, what the key terms and numbers actually mean for your health, and why some results matter more than others depending on what your doctor was looking for in the first place.
Why the Biopsy Was Ordered
Before diving into results, most reports open with a “clinical history” or “indication” line. This tells you what prompted the procedure. One of the most common reasons is unexplained low blood counts, which doctors call cytopenias. When routine blood tests can’t explain why your red cells, white cells, or platelets are low, a bone marrow biopsy can reveal problems that blood tests alone cannot detect.1Blood. Assessing bone marrow biopsy utility in patients with unexplained cytopenias Other common reasons include suspected leukemia, lymphoma, or myeloma; monitoring a known blood cancer’s response to treatment; evaluating unexplained fevers or infections; and staging cancers that may have spread to the bone marrow.
The indication matters because it shapes how you should read everything that follows. A report ordered to check for leftover leukemia after chemotherapy will emphasize blast counts and measurable residual disease. A report ordered for unexplained anemia might focus more on iron stores and whether the cells look normal as they mature. The pathologist interprets what they see through the lens of why the biopsy was done, and so should you.
The Three Sample Types You’ll See Referenced
Your report will mention up to three different preparations taken during the procedure, and each reveals something slightly different. The aspirate is liquid marrow pulled through a needle into a syringe, then smeared onto glass slides. It gives the best view of individual cell details: size, shape, the appearance of the nucleus. The trephine biopsy (or core biopsy) is a small cylinder of solid bone and marrow tissue, which is processed, sliced thin, and stained. It preserves the architecture of the marrow, showing how cells are arranged relative to one another. The touch imprint (or touch prep) is made by gently pressing the solid core against a slide before it goes into the fixative, leaving behind a thin stamp of cells that combines some advantages of both.
These preparations complement each other. The aspirate is better for examining individual cell detail and counting specific cell types. The core biopsy is the gold standard for assessing overall cellularity, detecting fibrosis, and spotting focal abnormalities like clusters of abnormal cells or granulomas that might be missed in a liquid sample.2PubMed Central. Comparison of bone marrow aspirate cytology, touch imprint cytology and trephine biopsy for bone marrow evaluation When performed together, they produce the highest diagnostic accuracy.3National Journal of Physiology, Pharmacy and Pharmacology. Correlation between bone marrow cytology, imprint, and biopsy in pancytopenia – A study in a tertiary care center in Eastern India If your report mentions a “dry tap” or “aspicular smear,” that means the liquid aspirate didn’t pull out enough marrow particles, which can limit what the pathologist can assess from the aspirate alone and makes the core biopsy even more important.
Cellularity and What the Percentage Means
One of the first numbers you’ll encounter is the cellularity estimate, expressed as a percentage. This tells you how much of the marrow space is occupied by blood-forming cells versus fat. A cellularity of 60% means roughly 60% of the marrow is active cells and 40% is fat. The pathologist usually calls the marrow normocellular, hypercellular, or hypocellular based on whether the number falls within, above, or below the expected range for your age.
Age matters here because healthy marrow naturally becomes less cellular over time. In adults, cellularity drops by roughly 3% per decade, and the normal range across adults aged 18 to 90 spans about 30% to 75%.4PubMed. Determination of age-dependent bone marrow normocellularity A 70-year-old with 35% cellularity may be perfectly normal, while the same number in a 25-year-old would raise concern. If your report says “hypocellular for age,” it means fewer blood-producing cells than expected, which can point toward aplastic anemia or other marrow failure conditions. “Hypercellular for age” can indicate that the marrow is working overtime, possibly because of a blood cancer driving excessive cell production, or sometimes just a reactive response to infection or inflammation.
Lineage Descriptions and the Myeloid-to-Erythroid Ratio
The marrow produces several families of blood cells. Your report will describe these lineages individually:
- Myeloid (granulocytic): the cells that become neutrophils, eosinophils, and basophils, which fight infections.
- Erythroid: the cells that become red blood cells, carrying oxygen.
- Megakaryocytic: the large cells that produce platelets for blood clotting.
For each lineage, the pathologist notes whether the cells appear adequate in number, whether they’re maturing normally through their stages, and whether they look morphologically normal. In a standard stained section, the pathologist can identify erythroid, myeloid, megakaryocytic, and stromal cells, plus fat tissue and iron-storing macrophages, though conclusively identifying lymphoid cells often requires additional stains.5PubMed Central. Enhanced histopathology of the bone marrow
You may also see a myeloid-to-erythroid (M:E) ratio, which compares the proportion of white cell precursors to red cell precursors. The normal range is roughly 2:1 to 4:1. A high ratio can mean the myeloid side is overproducing or the erythroid side is suppressed. A low ratio might indicate an expansion of red cell precursors, as in certain anemias. The ratio is a clue, not a diagnosis by itself, and the pathologist interprets it alongside everything else.
Blast Counts and Why They Get So Much Attention
Blasts are immature cells that haven’t yet developed into functioning blood cells. Everyone has a small number of blasts in their marrow, typically under 5%. The blast percentage is one of the most scrutinized numbers on the report because it directly affects diagnosis and classification. In acute myeloid leukemia (AML), the threshold that historically defined the disease was 30% blasts, but the widely used WHO classification lowered that to 20%.6PubMed Central. Treatment of acute myeloid leukemia with 20-30% bone marrow blasts This change means that some patients who would previously have been diagnosed with a pre-leukemic condition (myelodysplastic syndrome) are now classified as having AML.
If you’re reading a report after treatment for leukemia, the blast count takes on a different significance. Traditionally, fewer than 5% blasts was considered remission. But current expert recommendations from European hematology panels stress that morphology alone is no longer the final word. In acute lymphoblastic leukemia, measurable residual disease (MRD) testing by flow cytometry or molecular methods is now recommended as the gold standard for assessing remission, meaning a blast count below 5% doesn’t define remission if MRD testing is still positive, and a blast count at or above 5% doesn’t necessarily confirm active disease unless confirmed by an appropriate MRD assay.7Haematologica. Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA/ELN expert panel The same general principle applies in AML, where MRD negativity at a sensitivity of 0.1% or better is increasingly considered the deeper, more meaningful measure of remission.
Dysplasia and What “Abnormal-Looking Cells” Means
Dysplasia refers to cells that look abnormal as they mature. The report might describe features like oddly shaped red cell precursors (megaloblastoid changes, nuclear budding), white cell precursors with too few nuclear lobes (pseudo-Pelger-Huët cells), or unusually small megakaryocytes. In the context of myelodysplastic syndromes (MDS), dysplasia is a defining feature: the cells are being produced but they develop incorrectly, leading to blood counts that are chronically low despite a marrow that may look busy.
The standard threshold that counts as significant dysplasia is 10% or more of a given lineage showing abnormal features. But this threshold has been debated. A study of healthy bone marrow donors found that more than 10% dysplastic cells could be detected in nearly half of samples, with about a quarter showing dysplasia in two or more lineages.8PubMed Central. Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors This means seeing some dysplasia on a report doesn’t automatically mean MDS. The pathologist considers the degree, the specific types of abnormalities, and whether genetic testing supports a clonal process. Certain dysplastic features are far more specific than others. For instance, petal-shaped nuclei and internuclear bridging in the red cell line, or abnormally small megakaryocytes resembling lymphocytes, are more strongly associated with true MDS than generic changes that can appear in healthy marrows or as a result of vitamin deficiencies, medications, or infections.9PubMed. Characteristics of bone marrow cell dysplasia and its effectiveness in diagnosing myelodysplastic syndrome
Fibrosis Grading
Some reports include a fibrosis grade, which measures how much scar-like tissue (reticulin or collagen fibers) has replaced normal marrow. This is assessed using special stains on the core biopsy, most commonly a reticulin (silver) stain and, when needed, a trichrome stain for collagen. The WHO grading system uses a scale from MF-0 (no fibrosis) through MF-3 (severe fibrosis with thick collagen bundles and bone changes). Accurate grading is particularly important for diagnosing and predicting outcomes in myeloproliferative neoplasms like myelofibrosis, where fibrosis grade directly influences treatment decisions and prognosis.10PubMed. Applicability of the WHO grading for reticulin and collagen fibrosis in a routine diagnostic laboratory
One nuance worth knowing: reticulin staining alone may underestimate the degree of fibrosis. The same study found that collagen fibrosis graded higher than reticulin fibrosis in about 11% of cases, meaning the trichrome stain added diagnostic information that the silver stain missed. If your report mentions only reticulin grading without a trichrome, and the grade is above MF-1, you might ask whether a trichrome stain was performed.
Immunohistochemistry and Flow Cytometry
These sections of the report identify what types of cells are present based on the proteins (markers) on their surface or inside them, rather than just how the cells look under a microscope.
Immunohistochemistry (IHC) uses antibody-based stains applied to tissue sections from the core biopsy. Each stain highlights cells carrying a specific marker. For example, CD34 stains blast cells and is commonly used to count or locate them. In suspected plasma cell myeloma, markers like CD138 identify plasma cells, while CD56 helps distinguish malignant plasma cells from normal ones: about 63% of diagnosed myeloma cases express CD56, whereas reactive (non-cancerous) plasma cell increases do not.11PubMed Central. Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study Light chain staining (kappa and lambda) can reveal whether a population of plasma cells or B cells is clonal, meaning derived from a single abnormal parent cell, which is a hallmark of malignancy.
Flow cytometry works on liquid aspirate rather than solid tissue. It passes individual cells through a laser beam while they’re tagged with fluorescent antibodies, sorting them by their markers at very high speed. Flow cytometry can detect abnormal populations that are too small to see on a biopsy and is particularly powerful for identifying minimal residual disease. In B-cell disorders, flow cytometry sometimes catches disease that the biopsy misses, and vice versa, which is why both tests contribute to the final picture.12PubMed Central. A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders
Cytogenetics, FISH, and Molecular Testing
These are the genetic sections of the report, and they often take the longest to come back. They matter because many blood cancers are defined, classified, and risk-stratified by specific genetic abnormalities.
Conventional cytogenetics (karyotyping) involves growing marrow cells in culture, arresting them mid-division, and photographing the chromosomes to look for missing pieces, extra copies, or rearrangements. Karyotyping detects abnormalities at the level of individual cells and is uniquely able to show clonal evolution, where a cancer develops additional genetic changes over time.13Blood. Improving karyotype success for myelomatch: Evidence-based culturing optimization for rapid AML screening A normal karyotype is reported as “46,XX” or “46,XY.” Abnormalities show up as shorthand like “del(5q)” (deletion on chromosome 5’s long arm) or “t(15;17)” (a translocation between chromosomes 15 and 17).
Fluorescence in situ hybridization (FISH) uses fluorescent probes that bind to specific DNA sequences, letting the lab look for targeted abnormalities without needing cells to divide. FISH is an important complement to conventional karyotyping, especially when cultures fail or when the abnormality is too subtle for a karyotype to catch.14PubMed Central. Guidance for fluorescence in situ hybridization testing in hematologic disorders FISH panels are usually tailored to the suspected diagnosis. However, FISH has its own limitations: standard probe sets can miss rare or atypical rearrangements, and complementary molecular testing may be needed in those cases.15PubMed Central. Discrepancies in the Detection of PML::RARA Gene Rearrangement by Fluorescent In Situ Hybridization Using Commonly Used Dual Color Dual Fusion Probes
Molecular testing, increasingly performed by next-generation sequencing (NGS), looks for mutations at the DNA level. NGS panels can scan dozens of genes simultaneously, identifying mutations that help classify a disease, predict its behavior, and guide treatment choices.16PubMed Central. Next-Generation Sequencing Panel Test in Myeloid Neoplasms and Evaluation with the Clinical Results If your report lists mutations in genes like FLT3, NPM1, IDH1, IDH2, or TP53, these are among the mutations that directly influence prognosis and whether targeted therapies are available. NGS-based MRD testing is also emerging as a way to track whether leukemia cells persist at levels too low for the microscope to find, with MRD positivity after chemotherapy tending to be associated with shorter survival.17Annals of Laboratory Medicine. Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia
Iron Staining and Ring Sideroblasts
If your biopsy was ordered to evaluate anemia, the report may include results from a Prussian blue (Perl’s) iron stain performed on the aspirate. This stain reveals iron stores in the marrow and highlights sideroblasts: red cell precursors that have taken up iron into their mitochondria. Normal sideroblasts have a few scattered iron granules. Ring sideroblasts, where iron-laden mitochondria encircle the nucleus like a necklace, are a more specific finding. When ring sideroblasts make up 15% or more of erythroid precursors, they help define a subtype of MDS called MDS with ring sideroblasts. In one large review of 1,300 consecutive samples, about 17% of MDS patients met this threshold, and ring sideroblasts were also seen in some cases of MDS with excess blasts and AML with myelodysplasia-related changes. By contrast, ring sideroblasts were rare in blood cancers without dysplasia and in non-myeloid diseases.18PubMed Central. Bone marrow ring sideroblasts in hematological diseases: an analysis of consecutive 1300 samples in a single institution
Unexpected Findings
Sometimes a bone marrow biopsy reveals something that wasn’t the primary reason for the procedure. Granulomas, which are small clusters of immune cells forming a nodular reaction, are a classic example. They are relatively rare and usually incidental, but their presence triggers a workup for possible causes including infections such as tuberculosis and other mycobacterial diseases, autoimmune conditions, sarcoidosis, drug reactions, and occasionally cancers both hematologic and non-hematologic.19PubMed. Granulomas in bone marrow biopsies: clinicopathological significance and new perspectives Another example is finding metastatic solid tumor cells, such as breast or prostate cancer cells, that have spread to the marrow. The histological biopsy is considered the best way to catch these focal findings, since they can easily be missed in the liquid aspirate if the needle doesn’t sample the exact spot where they’re sitting.
Why the Report Arrives in Pieces
One of the most confusing aspects of a bone marrow biopsy is that the report often comes out in stages. You may see a preliminary report within a few days that covers the aspirate morphology and core biopsy appearance. Then addenda arrive over the following one to three weeks as flow cytometry, cytogenetics, FISH, and molecular results become available. Recommendations from Indian hematology groups emphasize that the integrated report should be released in a timely manner but also that the aspirate report should be followed up with the biopsy report, ideally reviewed by the same pathologist, to maintain continuity of interpretation.20Springer Link / Indian Journal of Hematology and Blood Transfusion. ICH-ISHBT Recommendations On Bone Marrow Aspiration/Imprint Smear Synoptic Reporting
The practical takeaway: don’t panic over a preliminary report that seems vague or inconclusive. Pathologists are often waiting for the genetic and molecular data before committing to a final diagnosis. The final, integrated interpretation at the bottom of the complete report is where the diagnosis crystallizes. Current standards of care emphasize integrating morphologic, immunophenotypic, and genetic features together rather than relying on any single component in isolation.21PubMed. Guide to the Diagnosis of Myeloid Neoplasms: A Bone Marrow Pathology Group Approach
Artifacts and Sampling Limitations
Bone marrow reports sometimes include disclaimers about sample quality, and understanding these can prevent misinterpretation. Improper or inadequate sampling is one of the most common reasons a biopsy fails to give a clear answer. Problems can arise at several points: the aspirate may be diluted with blood (hemodilution), the core biopsy may be too short to be representative, or the chemical decalcification process used to soften the bone tissue before slicing can damage proteins enough to cause immunohistochemistry stains to fail.22PubMed Central. Pitfalls in bone marrow evaluation: importance of adequate bone marrow sampling
If you see language in your report like “suboptimal specimen,” “hemodilute aspirate,” or “limited cellularity for evaluation,” it means the pathologist is flagging that the sample wasn’t ideal. This doesn’t mean the biopsy was done wrong — marrow conditions like fibrosis can make it physically difficult to pull out adequate material. But it does mean the findings should be interpreted cautiously, and a repeat biopsy may be recommended if clinical suspicion remains high. A synoptic report format, recommended by the College of American Pathologists, can help standardize what information is included and make it easier for both the treating physician and the patient to track what was assessed and what was limited.23PubMed. Bone Marrow Synoptic Reporting for Hematologic Neoplasms: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center
Reading the Final Interpretation
The last section of a complete bone marrow report is typically labeled “Interpretation,” “Diagnosis,” or “Comment.” This is where the pathologist pulls all the threads together. For lymphoid neoplasms, this means combining the blood counts, what the cells looked like under the microscope, what the immunophenotyping showed, and what the genetics revealed into a single unified diagnosis covering the full spectrum of B-cell, T-cell, and natural killer-cell diseases.24PubMed. Guide to the diagnosis of lymphoid neoplasms in blood and bone marrow: A Bone Marrow Pathology Group approach For myeloid diseases, the same integration is standard practice.
If the final interpretation doesn’t land on a single definitive diagnosis, it may list a differential — a short list of possible conditions ranked by likelihood. This isn’t a failure of the pathologist; some blood disorders genuinely require follow-up biopsies, additional clinical information, or the passage of time before they declare themselves. A report that honestly says “findings are consistent with X but Y cannot be excluded” is giving you more useful information than one that commits prematurely to a diagnosis the evidence doesn’t fully support. When reading your report, the final interpretation is the section to bring to your follow-up appointment and discuss line by line with your hematologist.